Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making
Caspar E.P. van Munster(Amphia Ziekenhuis), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), L. Genc Kaya(Amsterdam Neuroscience), Ka‐Hoo Lam(Amsterdam Neuroscience), Nynke F. Kalkers(OLVG), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 1
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient.
|PubMed|2017|1.8k